ASCO GUIDELINES Bundle

Salivary Gland Malignancy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475500

Contents of this Issue

Navigation

Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2021 All rights reserved. ASCOSAL02212 Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/head-neck-cancer- guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved. Recommendation Grading Type Evidence Quality Strength of Recommendation EB Evidence-based H High Strong CB/ FC Consensus-based/ Formal Consensus I Intermediate Moderate IC Informal consensus L Low Weak N No recommendation Ins Insufficient Abbreviations CT, computed tomography; IV, intravenous; MSRSGC, Milan System for Reporting Salivary Gland Cytopathology; MRI, magnetic resonance imaging ; MSI-H, microsatellite instability-high; PET/CT, positron emission tomography-computed tomography; ROHM, risk of high grade malignancy; ROM, risk of malignancy; RT, radiotherapy; SBRT, stereotactic body radiation; SGM, salivary gland malignancy Source Geiger JL, Ismaila N, Beadle B, et al. Management of Salivary Gland Malignancy. J Clin Oncol. 2021 April 26. doi: 10.1200/JCO.21.00449 ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/head-neck-cancer-guidelines.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Salivary Gland Malignancy